Anti-TNF Alpha Nanobody Producing Lactic Acid Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) like ulcerative colitis and Crohn's disease, which involve systemic administration of anti-TNFα antibodies, often result in serious side effects due to systemic delivery, and there is a need for a more effective and safer method to deliver biologically active TNF antibodies to the gastrointestinal tract.
Innovation Solution
Genetically modified lactic acid bacteria or yeast, such as Lactococcus lactis or Saccharomyces cerevisiae, are used to produce and deliver bivalent anti-TNFα nanobodies directly to the intestine, where they can inhibit TNF binding to its receptor, thereby treating IBD locally and reducing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of anti-TNFα antibodies is used to treat IBD, then therapeutic effectiveness is improved, but serious side effects occur due to systemic delivery
Solution Approach 1:
The patent applies local quality by using genetically modified lactic acid bacteria to deliver anti-TNFα antibodies specifically to the gastrointestinal tract where IBD occurs. This localized delivery ensures the therapeutic effect is concentrated at the disease site while minimizing systemic exposure and associated side effects.
Solution Approach 2:
The patent uses lactic acid bacteria as an intermediary carrier to transport and deliver anti-TNFα antibodies to the target site. These bacteria act as a mediator between the antibody and the intestinal tissue, enabling targeted delivery while protecting the antibody from premature degradation and reducing systemic circulation.
2Object-affected harmful factors
If genetically modified lactic acid bacteria are used to deliver anti-TNFα antibodies locally, then systemic side effects are reduced, but the complexity of the delivery system increases
Solution Approach 1:
The lactic acid bacteria are engineered to autonomously deliver the anti-TNFα antibodies to the gastrointestinal tract. The bacteria's natural ability to colonize the gut and their self-propelled movement eliminate the need for complex external delivery mechanisms, simplifying the overall system while achieving targeted delivery.
Solution Approach 2:
The lactic acid bacteria serve multiple functions: they act as a delivery vehicle for the antibody, colonize the gastrointestinal tract naturally, and provide a biocompatible platform. This multi-functionality reduces the need for separate components, thereby simplifying the delivery system.
3Ease of operation
If conventional anti-inflammatory drugs are used to treat IBD, then treatment is simple and widely available, but serious side effects occur and patient response varies
Solution Approach 1:
The patent changes the delivery parameter from systemic administration to localized gastrointestinal delivery. This parameter change ensures the antibody reaches the disease site directly, improving therapeutic consistency and reducing variability in patient response while maintaining ease of oral administration.
Data Source
AI summary
Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as Lactobacillus sp. and Saccharomyces sp., are disclosed for the treatment of chronic enterocolitis.